KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

About this update from Kalvista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data highlighting the burden of injectable on-demand treatment in children aged 2–11 with hereditary angioedema (HAE) presented at ISPOR 2026 and the Eastern Allergy Conference (EAC). “These data highlight the significant unmet needs that exist for children living with HAE and the families who care for them,” said Ben Palleiko, Chief Executive Officer of KalVista. “Currently, the only FDA-approved on-demand treatment for children ages 2–11 requires intravenous administration, which can place a considerable burden on both children and caregivers during already stressful attacks. Across real-world treatment patterns, healthcare resource utilization, and caregiver experiences, these findings reinforce the need for new treatment options that are easy to use and support early, consistent treatment of attacks. As the first and only oral on-demand treatment for HAE, EKTERLY® has the potential to meaningfully improve the treatment experience for this pediatric population and serve as a family-wide solution across generations.” On-Demand Treatments for Hereditary Angioedema and Healthcare Resource Utilization in Pediatric (2–11 Years) Patients: A US Claims Database Analysis was presented at ISPOR by Alice Wang, Senior Director, Global Health Economics and Value Demonstration, KalVista Pharmaceuticals. Real-world claims data showed that while about two thirds of children aged 2–11 were prescribed IV pdC1INH—the only FDA-approved on-demand HAE treatment for this population—the majority of treatments utilized were off-label (primarily icatibant), suggesting families and providers may be seeking less invasive treatment options. Although the mean on-demand dosing rate was 0.43 per patient per month, the rate for pdC1INH was far less (0.28) than that of icatibant (0.72). Healthcare resource utilization was substantial with 47% of patients requiring emergency room care and 17% utilizing home-health services. Burden of Injectable On-Demand Treatment for Hereditary Angioedema Attacks in Children will be presented at EAC by Timothy Craig, DO, Professor, Departments of Medicine and Pediatrics, Division of Pulmonary, Allergy and Critical Care Medicine, Penn State Health. A caregiver survey found that nearly half of children did not receive on-demand treatment for their most recent HAE attack. Among children who...

View stock analysis, news, and events for Kalvista Pharmaceuticals, Inc.